Pfizer Voluntarily Withdraws Sickle Cell Disease Treatment Oxbryta From Global Market Due To Painful Disease Complication, Deaths (UPDATED)
Portfolio Pulse from Vandana Singh
Pfizer has voluntarily withdrawn its sickle cell disease treatment, Oxbryta, from the global market due to safety concerns, including painful complications and deaths. The company has also halted all related clinical trials and does not expect this to impact its 2024 financial guidance.
September 26, 2024 | 2:29 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Pfizer has withdrawn Oxbryta from the market due to safety concerns, including painful complications and deaths. The company has also stopped all related clinical trials. Despite this, Pfizer does not expect an impact on its 2024 financial guidance.
The withdrawal of Oxbryta due to safety concerns is a significant event, as it affects Pfizer's product portfolio and ongoing clinical trials. However, Pfizer's statement that this will not impact its 2024 financial guidance suggests limited financial impact. The stock price may see short-term negative pressure due to the withdrawal and safety concerns.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100